108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
康柏西普玻璃体内注射在增殖性糖尿病视网膜病变玻璃体切除术中的疗效：一项整合荟萃分析和文献计量学研究
Authors Li G, Zhang M, Ke Y, Zheng C, Tan L, Li Y, Pazo EE , Chen C, Ren X
Received 14 January 2025
Accepted for publication 22 July 2025
Published 19 September 2025 Volume 2025:19 Pages 3465—3486
DOI https://doi.org/10.2147/OPTH.S516425
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Scott Fraser
Guangda Li,1,* Mingxuan Zhang,2,* Yifeng Ke,2 Chuanzhen Zheng,3 Liangzhang Tan,2 Yongtao Li,2 Emmanuel Eric Pazo,2 Chunli Chen,4 Xinjun Ren2
1Department of Ophthalmology, Linyi People’ s Hospital, Linyi, Shandong, People’s Republic of China; 2Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People’s Republic of China; 3Department of Ophthalmology, Sichuan Provincial People’s Hospital, Chengdu, People’s Republic of China; 4Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chunli Chen, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100010, People’s Republic of China, Email chenchunli125@163.com Xinjun Ren, Tianjin Medical University Eye Hospital, 251 Fu Kang Road, Tianjin, 300384, People’s Republic of China, Email xin2023ren@tmu.edu.cn
Purpose: To evaluate the effectiveness of intravitreal Conbercept administered before or during vitrectomy in patients with proliferative diabetic retinopathy (PDR), additionally, a bibliometric analysis was performed.
Methods: The literature search was conducted using keywords and terms combined as follows: “conbercept”, “vitrectomy”, and “proliferative diabetic retinopathy”, from January 2012 to August 2024. Additionally, we conducted three different comparisons. Data for the bibliometric analysis were obtained from the Web of Science database and analyzed using VOSviewer and Bibliometrix applications.
Results: A total of 16 studies encompassing 1,215 cases were analyzed in this review. Patients in the Conbercept group demonstrated significantly greater improvements in best corrected visual acuity (BCVA) compared to the no injection group at six-month follow-ups (MD = – 0.36, 95% CI – 0.45 to – 0.28, P < 0.01). Additionally, the Conbercept group experienced fewer intraoperative complications, including reduced incidences of intraoperative bleeding (OR = 0.12, 95% CI 0.07 to 0.21), use of endodiathermy (OR = 0.26, 95% CI 0.15 to 0.47), silicone oil tamponade (OR = 0.50, 95% CI 0.35 to 0.73), and iatrogenic breaks (OR = 0.25, 95% CI 0.13 to 0.48). Both early and late postoperative vitreous hemorrhages were less common in the Conbercept group. When administered during vitrectomy, Conbercept still showed superior BCVA improvement at six months (MD = – 0.32, 95% CI – 0.46 to – 0.18, P < 0.01). No significant difference was found between Conbercept and Ranibizumab in BCVA or intraoperative outcomes. From 2015 to 2025, 5,065 publications on Conbercept emerged, with declining growth but strong global collaboration and relevance in anti-VEGF ocular therapy.
Conclusion: This systematic review revealed that, similarly to other anti-VEGF injections, Conbercept injection improved BCVA and had lower rates of intraoperative and postoperative complications. Conbercept research shows strong global collaboration and evolving focus on clinical applications in retinal vascular disease management.
Keywords: proliferative diabetic retinopathy, conbercept, ranibizumab, vitrectomy, BCVA
1Department of Ophthalmology, Linyi People’ s Hospital, Linyi, Shandong, People’s Republic of China; 2Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People’s Republic of China; 3Department of Ophthalmology, Sichuan Provincial People’s Hospital, Chengdu, People’s Republic of China; 4Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chunli Chen, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100010, People’s Republic of China, Email chenchunli125@163.com Xinjun Ren, Tianjin Medical University Eye Hospital, 251 Fu Kang Road, Tianjin, 300384, People’s Republic of China, Email xin2023ren@tmu.edu.cn
Purpose: To evaluate the effectiveness of intravitreal Conbercept administered before or during vitrectomy in patients with proliferative diabetic retinopathy (PDR), additionally, a bibliometric analysis was performed.
Methods: The literature search was conducted using keywords and terms combined as follows: “conbercept”, “vitrectomy”, and “proliferative diabetic retinopathy”, from January 2012 to August 2024. Additionally, we conducted three different comparisons. Data for the bibliometric analysis were obtained from the Web of Science database and analyzed using VOSviewer and Bibliometrix applications.
Results: A total of 16 studies encompassing 1,215 cases were analyzed in this review. Patients in the Conbercept group demonstrated significantly greater improvements in best corrected visual acuity (BCVA) compared to the no injection group at six-month follow-ups (MD = – 0.36, 95% CI – 0.45 to – 0.28, P < 0.01). Additionally, the Conbercept group experienced fewer intraoperative complications, including reduced incidences of intraoperative bleeding (OR = 0.12, 95% CI 0.07 to 0.21), use of endodiathermy (OR = 0.26, 95% CI 0.15 to 0.47), silicone oil tamponade (OR = 0.50, 95% CI 0.35 to 0.73), and iatrogenic breaks (OR = 0.25, 95% CI 0.13 to 0.48). Both early and late postoperative vitreous hemorrhages were less common in the Conbercept group. When administered during vitrectomy, Conbercept still showed superior BCVA improvement at six months (MD = – 0.32, 95% CI – 0.46 to – 0.18, P < 0.01). No significant difference was found between Conbercept and Ranibizumab in BCVA or intraoperative outcomes. From 2015 to 2025, 5,065 publications on Conbercept emerged, with declining growth but strong global collaboration and relevance in anti-VEGF ocular therapy.
Conclusion: This systematic review revealed that, similarly to other anti-VEGF injections, Conbercept injection improved BCVA and had lower rates of intraoperative and postoperative complications. Conbercept research shows strong global collaboration and evolving focus on clinical applications in retinal vascular disease management.
Keywords: proliferative diabetic retinopathy, conbercept, ranibizumab, vitrectomy, BCVA